UpdatesPress Release
Anthem Biosciences posted robust FY26 results.
Anthem Biosciences LimitedANTHEM · Filed with the exchange
FY26 revenue grew 15.2% to ₹2,124.3 Cr, with PAT up 31.1% to ₹591.8 Cr.
Q4 revenue jumped 26.4% to ₹610.9 Cr, and PAT surged 129.8% to ₹189.8 Cr.
Strong CRDMO performance.
No comments yet. Be the first.